Sun Pharmaceutical Industries has launched Favipiravir (200 mg) in India under the brand FluGuard to treat mild to moderate COVID-19 disease. Favipiravir, the only oral anti-viral treatment approved in the country against COVID-19, was launched at an economical price of of Rs 35 per tablet.
Kirti Ganorkar, CEO of India Business at Sun Pharma, said in a statement that there is an urgent need to provide more treatment options to healthcare professionals since over 50000 cases are reported daily in India.
"We are launching FluGuard at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden. This is in line with our continuous efforts to support India’s pandemic response," Ganorkar said.
The company said it will work closely with the government and medical community to ensure availability of FluGuard to patients across the country. The stocks of FluGuard will be available in the market from this week.
Sun Pharma is India's leading pharmaceutical company and the world's fourth largest specialty generic pharmaceutical company.
